Peptides for post-cancer neuropathy

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 70% of cancer patients, leading to debilitating symptoms like pain, numbness, tingling, and loss of sensation, often persisting long after treatment ends [Nagata, 2019].. This nerve damage significantly impairs quality of life and can limit treatment options.

Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 70% of cancer patients, leading to debilitating symptoms like pain, numbness, tingling, and loss of sensation, often persisting long after treatment ends [Nagata, 2019]. This nerve damage significantly impairs quality of life and can limit treatment options. Peptides offer targeted neuroprotective and regenerative strategies to mitigate CIPN and promote nerve recovery.

Glutathione: A Key Neuroprotective Tripeptide

Glutathione (GSH), a naturally occurring tripeptide (gamma-L-glutamyl-L-cysteinylglycine), is the body’s master antioxidant and plays a critical role in detoxifying chemotherapy agents and protecting nerve cells from oxidative stress. Chemotherapy drugs like oxaliplatin and paclitaxel deplete GSH levels, contributing to nerve damage [Nagata, 2019]. Supplementation with GSH has shown promise in preventing and reducing CIPN.

A randomized, double-blind, placebo-controlled trial (NCT00979082) investigated glutathione’s role in preventing paclitaxel and carboplatin-induced neuropathy, demonstrating its neuroprotective effects. In another study, reduced glutathione was shown to have a neuroprotective effect on oxaliplatin-based chemotherapy in advanced colorectal cancer [ONS, n.d.]. While specific dosing can vary, intravenous GSH at 1500 mg before and after chemotherapy cycles has been explored in clinical settings to maintain optimal levels and protect against neuropathy. Oral liposomal GSH may also be considered for ongoing support.

BPC-157: Regenerative Potential for Nerve Repair

BPC-157 (Body Protection Compound-157), a stable gastric pentadecapeptide, is widely recognized for its regenerative and cytoprotective properties across various tissues, including the nervous system. It has demonstrated neuroprotective effects and promotes nerve regeneration in preclinical models of nerve injury [Seiwerth et al., 2018]. BPC-157’s mechanism involves modulating growth factors, promoting angiogenesis, and reducing inflammation, all of which are crucial for nerve repair and recovery.

In animal studies, BPC-157 has shown antinociceptive effects in pain models and has been implicated in the healing of various lesions, including those in the nervous system [Seiwerth et al., 2018; Sikiric et al., 2010]. While its direct application for CIPN in humans is still under investigation, its regenerative capacity suggests a potential role in promoting nerve healing and reducing neuropathic pain. Typical research dosages in animal models range from 1-10 µg/kg. However, as previously discussed, the pro-angiogenic properties of BPC-157 raise theoretical concerns about inadvertently promoting residual tumor growth or metastasis in cancer survivors [Prisk, 2025]. This necessitates extreme caution and thorough oncological clearance before considering its use in this population.

ACTH/MSH-Derived Peptides: Modulating Nerve Plasticity

Peptides derived from Adrenocorticotropic Hormone (ACTH) and Melanocyte-Stimulating Hormone (MSH) have been studied for their neurotrophic and neuroprotective effects, influencing nerve plasticity and repair. These peptides can promote nerve regeneration, reduce inflammation, and improve functional recovery after nerve damage [Schoenen et al., 2008]. While not yet widely used in clinical practice for CIPN, their mechanisms of action suggest a potential future role in modulating nerve health post-cancer.

Comparison: Direct Protection vs. Regenerative Potential

The distinction between Glutathione and BPC-157 in managing post-cancer neuropathy lies in their primary mechanisms and oncological safety profiles. Glutathione offers direct neuroprotection by combating oxidative stress and detoxifying chemotherapy agents, with a well-established safety record in cancer patients. Its role is primarily preventive and mitigative against the direct insult of chemotherapy. BPC-157, conversely, offers potent regenerative potential, actively promoting nerve repair and healing. However, its pro-angiogenic properties introduce a significant oncological caveat, making its use in cancer survivors a complex decision requiring careful risk-benefit analysis and oncological oversight. While both aim to improve nerve health, GSH is a safer, more direct neuroprotective agent, whereas BPC-157’s regenerative benefits must be weighed against its theoretical oncological risks.

Clinical Takeaway

For cancer survivors experiencing neuropathy, proactive management is crucial. Intravenous glutathione at 1500 mg before and after chemotherapy cycles can significantly reduce the incidence and severity of CIPN by directly mitigating oxidative stress. For ongoing support, oral liposomal GSH may be considered. While BPC-157 shows promising regenerative effects for nerve repair, its pro-angiogenic properties necessitate extreme caution and thorough oncological clearance before use in cancer survivors. Prioritize peptides with established neuroprotective benefits and a favorable safety profile in oncology, and always monitor neurological symptoms and patient-reported outcomes to guide therapy. A multidisciplinary approach involving oncologists, neurologists, and pain specialists is essential for comprehensive neuropathy management.

References